CRISPR THERAPEUTICS AG Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CRISPR THERAPEUTICS AG stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $8.51M, a 256.00% increase year-over-year.
- CRISPR THERAPEUTICS AG stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $5.62M, a 344.54% increase year-over-year.
- CRISPR THERAPEUTICS AG stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $17.61M, a 541.11% increase year-over-year.
- CRISPR THERAPEUTICS AG stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $2.39M, a 123.46% increase year-over-year.
- CRISPR THERAPEUTICS AG stock issued during period, value, stock options exercised for fiscal 2025 was $26.31M, a 11.07% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG stock issued during period, value, stock options exercised for fiscal 2024 was $29.58M, a 5.25% increase from fiscal 2023.
- CRISPR THERAPEUTICS AG stock issued during period, value, stock options exercised for fiscal 2023 was $28.10M, a 21.53% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG stock issued during period, value, stock options exercised for fiscal 2022 was $35.81M, a 0.17% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $8.51M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $5.62M 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $26.31M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $17.61M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $2.39M 10-Q · filed 2026-08-03 | |
| 2025-03-31 | $1.26M 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $29.58M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $2.75M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $1.07M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $23.87M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $28.10M 10-K · filed 2026-02-12 | |
| 2023-09-30 | $647.00K 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $16.62M 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $4.68M 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $35.81M 10-K · filed 2025-02-11 | |
| 2022-09-30 | $12.78M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $10.35M 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $10.01M 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $35.87M 10-K · filed 2024-02-21 | |
| 2021-09-30 | $8.88M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $10.91M 10-Q · filed 2022-11-01 | |
| 2021-03-31 | $9.78M 10-Q · filed 2022-11-01 | |
| 2020-12-31 | $32.77M 10-K · filed 2023-02-21 | |
| 2020-09-30 | $12.66M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $6.34M 10-Q · filed 2021-11-03 | |
| 2020-03-31 | $1.39M 10-Q · filed 2021-11-03 | |
| 2019-12-31 | $16.00M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $2.34M 10-Q · filed 2020-10-28 | |
| 2019-06-30 | $1.25M 10-Q · filed 2020-10-28 | |
| 2019-03-31 | $1.83M 10-Q · filed 2020-10-28 | |
| 2018-12-31 | $8.56M 10-K · filed 2021-02-16 | |
| 2018-09-30 | $1.84M 10-Q · filed 2019-10-28 | |
| 2018-06-30 | $3.73M 10-Q · filed 2019-10-28 | |
| 2018-03-31 | $2.66M 10-Q · filed 2019-10-28 | |
| 2017-12-31 | $2.61M 10-K · filed 2020-02-12 | |
| 2016-12-31 | $35.00K 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |